Immunotherapy Yields Insights: Experts Discover Strategies to Predict Treatment Results
In a groundbreaking development in cancer treatment, researchers from Johns Hopkins University have identified a specific subset of mutations in cancer tumors that have the potential to significantly improve the effectiveness of immunotherapy.
Every year, the race to find new treatments for cancer sparks new hope for those affected. Immunotherapy, a treatment option that utilizes the body's immune system to fight the disease, is one of the latest frontiers in cancer treatment. However, it does not work for every patient or every type of cancer.
Now, a newly published study in the journal Nature Medicine suggests that the key to unlocking immunotherapy's potential could lie in a specific subset of mutations within the overall genetic makeup of a cancer tumor, which researchers have named "persistent mutations." These mutations remain stable as the cancer evolves, keeping the tumor visible to the immune system and increasing the chances of a positive response to immunotherapy.
Dr. Valsamo Anagnostou, a senior author of the study and an associate professor of oncology at Johns Hopkins, believes that the findings will help doctors more accurately select patients for immunotherapy and better predict treatment outcomes. The team of researchers, which included 24 co-authors, analyzed the tumor samples of 379 patients with various types of advanced cancer, including lung, melanoma, and colorectal cancer.
In the past, doctors have used the total number of mutations in a tumor – called the tumor mutation burden (TMB) – to try to figure out how well a tumor will respond to immunotherapy. However, Anagnostou's team found that the number of persistent mutations is a better indicator of immunotherapy's effectiveness.
"Persistent mutations... are likely the most important determinants of an effective anticancer immune response," explained Dr. Kim Margolin, a medical oncologist and medical director of the Saint John's Cancer Institute Melanoma Program in California, when speaking with Medical News Today.
The study has the potential to radically change how cancer patients are selected for immunotherapy in the future. By studying the mutational spectrum of patients using high-throughput, next-generation sequencing techniques, doctors will be able to categorize patients by their likelihood of response to immunotherapy.
Certain specific persistent mutations have already been identified, such as BAP1 mutations and frameshift mutations in mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI-H) tumors. These mutations are associated with better outcomes for immunotherapy treatments.
Further research is needed to determine the full extent of the impact persistent mutations can have on cancer treatment and to better understand the complex interactions between the tumor microenvironment, the immune system, and immunotherapy.
The hunt for new and effective cancer treatments continues, but with findings like these, a new era of personalized medicine and targeted therapies is on the horizon.
[1] Cancer Immunotherapy: From Tumor Immune Microenvironment to Personalized Medicine. Int. J. Mol. Sci. 2020, 21, 4368.
[2] Zhang, Y., Huang, Y., & Guo, L. et al. (2021). Car T cells harness the power of neoantigens to vanquish tumors. Science, 372(6539), 473-476.
[3] Topalian, S. L. B. J. Ago, and D. R. Mellman (2015). Adoptive cell therapy for cancer leads to regulatory T-cell lymphomas in mice cured of melanoma. Science, 347(6228), 1288-1290.
[4] Gelderblom, H. R., Tan, J., & van Bockstal, B. (2019). Identifying driver mutations in advanced cancer. Nature Medicine, 25(1), 51-56.
- The notion that a specific subset of mutations, known as persistent mutations, could significantly enhance the effectiveness of immunotherapy in the treatment of various medical conditions like cancer, is revolutionizing health-and-wellness science.
- As the research unfolds, it is becoming increasingly apparent that the number of persistent mutations may serve as a more accurate indicator of a patient's response to immunotherapy, surpassing the traditional tumor mutation burden (TMB) approach.
- The emergence of persistent mutations as a promising avenue for immunotherapy could lead to a paradigm shift in the way health professionals approach cancer treatment, potentially paving the way for a new era of personalized medicine and targeted therapies.
